ealantis, which was established in Israel on the basis of technology developed at the Technion Institute, has been sold for US$25 million and royalties from future sales to Advanced Medical Solutions Group from England.
Sealantis develops medical adhesives based on technology from the Technion, which mimics the mechanism of adhesion of algae to rocks in water. “This is fundamental research inspired by a natural phenomenon that developed into applied technology, was patented and eventually became a product that will enable hundreds of thousands of patients to be treated.”
AMS, the acquiring company, is a manufacturer of innovative and technologically advanced products for the global surgical, wound closure and advanced wound care markets. This is their first acquisition in Israel, and Sealantis will be an innovation center for the multinational group. AMS’s products are sold in more than 75 countries, and the group has more than 600 employees.
Sealantis develops medical device products, based on a proprietary platform of alga-mimetic tissue adhesives, for a variety of applications in surgical adhesion. The company was established under the auspices of the AMIT Institute at the Technion, under the leadership of Prof. Havazelet Bianco-Peled, a world-renowned expert in biomedical polymers, from the Faculty of Chemical Engineering at the Technion.
The company’s present focus is on surgical seals designed to stop bleeding, prevent leakage of digestive tract contents into the abdominal cavity, prevent leakage of spinal fluid, and a variety of other applications.
The leading advantage of the technology is the fact that it is based on a polymer produced from algae, which does not contain proteins, and therefore the risk of infection or allergy is significantly lower than that of competing products produced from animals. The product does not require refrigerated transport and storage, it can be applied by spreading or spraying and is also suitable for use in laparoscopic surgery.
Tomer Fuchs, CEO of Sealantis, said that the connection with AMS increases the potential impact of the company’s products. “The journey of Sealantis is underway. The merger into AMS is an important milestone in the realization of our vision to enable medical teams around the world to prevent serious surgical complications thanks to Sealantis’ products.
“Following the merger, AMS will enjoy our scientific and engineering capabilities as an Israeli start-up company in the field of biotechnology, which includes innovation and the ability to bring simple and original solutions to complex challenges. AMS plans to expand operations in Israel, enabling it to expand into new, significant directions.”